


IN THE CLAIMS:

Kindly replace claims 1-3, 6, and 14-17 as follows.

1. (Amended) A quinazoline derivative having the following formula (1) and a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R¹ represents (a) hydroxyl group, (b) an amino group; (c) a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, (d) a C₇ and C₁₀ lower aralkylamino group which may be substituted with a COOH group, (e) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (f) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (g) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (h) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (i) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (j) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, (k) a C₁

to C₄ lower alkyl group substituted with a COOH group, or (l) a C₂ to C₄ lower alkenyl group which may be substituted with a COOH group;

D1
Cont
C3
R² and R³ may be the same or different and represent (a) a hydrogen atom, (b) an unsubstituted or substituted C₁ to C₄ lower alkyl group, (c) a halogen atom, (d) a hydroxyl group, (e) a C₁ to C₄ lower alkoxy group, (f) an amino group, (g) an unsubstituted or substituted C₁ to C₄ lower alkylamino group, (h) an unsubstituted or substituted C₁ to C₁₀ aralkylamino group, (i) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

when the ring A is benzene ring, R¹ and R² may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R³ is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group, (c) a C₁ to C₄ lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, (e) an amino group, or (g) a

~~DI
cont~~ nitro group, with the proviso that, when A is a benzene ring and R¹ is an amino group, R² and R³ are not a hydrogen atom at the same time.

~~2. (Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R¹ is a hydroxyl group, an amino group, a C₁ to C₄ lower alkylamino group substituted with a COOH group, or an amino group acylated with a C₁ to C₄ lower aliphatic acid substituted with a COOH group.~~

~~3. (Twice Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R² is a COOH group or a hydrogen atom.~~

~~6. (Twice Amended) A chymase inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically salt according to claim 1, and a pharmaceutically acceptable carrier therefor.~~

~~14. (Amended) A method for treatment of allergic diseases or rheumatic diseases comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.~~

~~15. (Amended) A method for treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis or rheumatoid arthritis comprising administering to a~~

patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

Sub
E1
CS

16. (Amended) A method for treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

17. (Amended) A method for treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including cardiac infarction, angioendothelia or vascular disorders accompanying arterialization and atheroma comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.